Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17097623 | 1.00 | HSD11B1 (0.35) | HSD11B1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL17049044 | 0.89 | HSD11B1 (0.31) | HSD11B1 | |
| SCHEMBL17098874 | 0.89 | HSD11B1 (0.31) | HSD11B1 | |
| SCHEMBL17097963 | 0.89 | ALDH1A1 (0.33) | HSD11B1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL17097965 | 0.89 | ALDH1A1 (0.33) | HSD11B1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL17099128 | 0.87 | HSD11B1 (0.34) | HSD11B1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL17099129 | 0.87 | HSD11B1 (0.34) | HSD11B1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL17098234 | 0.85 | HSD11B1 (0.34) | HSD11B1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL17098231 | 0.85 | HSD11B1 (0.34) | HSD11B1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL17097867 | 0.82 | ALDH1A1 (0.34) | HSD11B1ALDH1A1SMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365522-B2 | Pyrazole amide derivative | AMGEN INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150266824-A1 | Pyrazole Amide Derivative | TEIJIN LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266824-A1 | Pyrazole Amide Derivative | RORC, RORB, RORA | HSD11B1 195/4885ALDH1A1 923/4885KDM4E 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.